Place of sorafenib in the treatment of hepatocellular carcinoma
Authors:
P. Tesařová
Authors‘ workplace:
Onkologická klinika 1. LF UK a VFN Praha
Published in:
Gastroent Hepatol 2010; 64(5): 15-21
Category:
Review Article
Overview
The advancement in the systemic treatment of hepatocellular carcinoma (HCC) has improved prospects for the overall survival rate in patients with the advanced form of the tumour. In this overview, the new targeted therapy is set in the context of both traditional and the latest therapeutical methods, which include – besides liver transplant, partial hepatectomy, radiofrequency ablation and alcoholization – also radiotherapy, immunotherapy, chemotherapy and biological therapy. Local therapy is usually preferred to systemic therapy. Patients for whom locoregional therapy is not suitable due to advanced disease can benefit from systemic therapy. The targeted therapy with sorafenib, a multiple tyrosine kinase inhibitor, which was proven in the SHARP study to produce a statistically significant improvement in the overall survival rate of patients with advanced HCC, has become a new standard in systemic therapy of advanced HCC. Sorafenib demonstrated high efficacy in monotherapy compared to the placebo and is the first and so far only drug which has significantly improved the overall survival rate in patients with HCC. Other biological drugs include bevacizumab, sunitinib and erlotinib. To conclude, current recommendations on HCC treatment are presented.
Key words:
hepatocellular carcinoma – liver cirrhosis – sorafenib
Sources
1. Mínguez B, Tovar V, Chiang D et al. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol 2009; 25(3): 186–194.
2. Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol 2008; 20(4): 444–453.
3. Luna LE, Kwo PY, Roberts LR et al. Liver transplantation after radioembolization in a patient with unresectable HCC. Nat Rev Gastroenterol Hepatol 2009; 6(11): 679–683.
4. Nguyen KT, Gamblin TC, Geller DA. World review of laparoscopic liver resection-2,804 patients. Ann Surg 2009; 250(5): 831–841.
5. Padma S, Martinie JB, Iannitti DA. Liver tumor ablation: percutaneous and open approaches. J Surg Oncol 2009;100(8): 619–634.
6. Palussičre J, Descat E, Fonck M et al. [Radiofrequency ablation in the treatment of liver and lung tumors]. Bull Cancer 2009; 96(11): 1099–1109.
7. Forner A, Trinchet JC.Transarterial therapies in HCC: does embolization increase survival? J Hepatol 2009; 51(6): 981–983.
8. Mohnike K, Wieners G, Pech M et al. Image-guided interstitial high-dose-rate brachytherapy in hepatocellular carcinoma. Dig Dis 2009; 27(2): 170–174.
9. Shim JH, Park JW, Nam BH et al. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009; 63(3): 459–467.
10. Lee JO, Lee KW, Oh DY et al. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol 2009; 20(8): 1402–1407.
11. Parikh PM, Fuloria J, Babu G et al. A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma. Trop Gastroenterol 2005; 26(3): 115–118.
12. Chia WK, Ong S, Toh HC et al. Phase II Trial of Gemcitabine in Combination with Cisplatin in Inoperable or Advanced Hepatocellular Carcinoma. Ann Acad Med Singapore 2008; 37(7): 554–558.
13. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009; 6(10): 569–579. Epub 2009 Sep 8.
14. Llovet JM, Sala M, Castells L et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31(1): 54–58.
15. Kerr SH, Kerr DJ. Novel treatments for hepatocellular cancer. Cancer Lett 2009; 286(1): 114–120.
16. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69(2): 223–240.
17. Thomas M. Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol 2009; 44 (Suppl 19): 136–141.
18. Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 2008; 75 (Suppl 1): 1–12.
19. Kane RC, Farrell AT, Madabushi R et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 2009; 14(1): 95–100.
20. Greten TF, Korangy F, Manns MP et al. Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer 2009; 100(1): 19–23.
21. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24(26): 4293–4300.
22. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378–390.
23. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10(1): 25–34.
24. Raoul J, Santoro A, Beaugrand M et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: a subanalysis from the SHARP trial (abstract). J Clin Oncol 2008; 26: 234.
25. Huitzel-Melendez FD, Saltz LB, Song J et al. Retrospective analysis of outcome in hepatocellular carcinoma (HCC) patients with hepatitis C (C+) versus B (B+) treated with sorafenib (abstract). Data preseted at the 2007 ASCO Gastrointestinal Cancers Symposium, January 19–21st, 2007, Orlando, FL.
26. Bolondi L, Caspary W, Bennouna J et al. Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): subgroup analysis of the SHARP trial (abstract). Data presented at the 2008 ASCO Gastrointestinal Cancers Symposium, Orlando, FL, January 25–27, 2008. (abstract 129).
27. D‘Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 2006; 44(1): 217–231.
28. Abou-Alfa GK, Amadori D, Santoro A et al. Is sorafenib safe and effective in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis? (abstract). J Clin Oncol 2008.
29. Zhu AX, Duda DG, Sahani DV et al. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J 2009; 15(4): 263–268.
30. Mendizabal M, Reddy KR. Current management of hepatocellular carcinoma. Med Clin North Am 2009; 93(4): 885–900.
31.Wörns MA, Weinmann A, Schuchmann M et al. Systemic therapies in hepatocellular carcinoma. Dig Dis 2009; 27(2): 175–188.
32. Finn RS, Zhu AX. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 2009; 9(4): 503–509.
33. Oseini AM, Roberts LR. PDGF Ralpha: a new therapeutic target in the treatment of hepatocellular carcinoma? Expert Opin Ther Targets 2009; 13(4): 443–454.
34. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48(4): 1312–1327.
35. Verslype C, Van Cutsem E, Dicato M et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol 2009; 20 Suppl 7: vii1-vii6.
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
2010 Issue 5
Most read in this issue
- Prof. MUDr. Jiří Ehrmann CSc. turned seventy
- Treatment of patients with acute pancreatitis in the Slovak Republic – survey
- Place of sorafenib in the treatment of hepatocellular carcinoma
- Comparative Analysis of the Results of Laparoscopic and Traditional Cholecystectomy in the Patients with Acute Cholecystitis